Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2017, Article ID 6294717, 11 pages
https://doi.org/10.1155/2017/6294717
Research Article

Mesenchymal Stem Cells Promote Metastasis of Lung Cancer Cells by Downregulating Systemic Antitumor Immune Response

1Department of Genetics, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
2Department of Microbiology and Immunology, Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 69 Svetozar Markovic Street, 34000 Kragujevac, Serbia
3Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
4Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia
5Institute of Anatomy, University of Bern, 3000 Bern 9, Switzerland
6Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

Correspondence should be addressed to Vladislav Volarevic; moc.oohay@civeralovrd

Received 9 March 2017; Revised 4 June 2017; Accepted 5 June 2017; Published 16 July 2017

Academic Editor: Franca Fagioli

Copyright © 2017 Marina Gazdic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Gazdic, V. Volarevic, N. Arsenijevic, and M. Stojkovic, “Mesenchymal stem cells: a friend or foe in immune-mediated diseases,” Stem Cell Reviews and Reports, vol. 11, no. 2, pp. 280–287, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Gebler, O. Zabel, and B. Seliger, “The immunomodulatory capacity of mesenchymal stem cells,” Trends in Molecular Medicine, vol. 18, no. 2, pp. 128–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Tao, Z. Han, Z. C. Han, and Z. Li, “Proangiogenic features of mesenchymal stem cells and their therapeutic applications,” Stem Cells International, vol. 2016, Article ID 1314709, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. M. M. Lalu, L. McIntyre, C. Pugliese et al., “Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials,” PLoS One, vol. 7, no. 10, article e47559, 2012. View at Google Scholar
  5. P. C. Hackler, S. Reuss, R. L. Konger, J. B. Travers, and R. P. Sahu, “Systemic platelet-activating factor receptor activation augments experimental lung tumor growth and metastasis,” Cancer Growth Metastasis, vol. 7, pp. 27–32, 2014. View at Publisher · View at Google Scholar
  6. Y. Mao, D. Yang, J. He, and M. J. Krasna, “Epidemiology of lung cancer,” Surgical Oncology Clinics of North America, vol. 25, no. 3, pp. 439–445, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. I. Linero and O. Chaparro, “Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration,” PLoS One, vol. 9, no. 9, article e107001, 2014. View at Google Scholar
  8. S. H. Yang, M. J. Park, I. H. Yoon et al., “Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10,” Experimental & Molecular Medicine, vol. 41, no. 5, pp. 315–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Ren, L. Zhang, X. Zhao et al., “Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide,” Cell Stem Cell, vol. 2, no. 2, pp. 141–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M. S. Tsai, C. C. Chang, M. L. Kuo, and Y. T. Wu, “Vascular endothelial growth factor-A and changes in a tumor-bearing mouse model with Lewis lung cancer,” Oncolology Letters, vol. 2, no. 6, pp. 1143–1147, 2011. View at Google Scholar
  11. E. P. Amaral, S. C. Ribeiro, V. R. Lanes et al., “Pulmonary infection with hypervirulent mycobacteria reveals a crucial role for the P2X7 receptor in aggressive forms of tuberculosis,” PLoS Pathogens, vol. 10, no. 7, article e1004188, 2014. View at Google Scholar
  12. W. Ling, J. Zhang, Z. Yuan et al., “Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment,” Cancer Research, vol. 74, no. 5, pp. 1576–1587, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Wang, X. Zhang, Y. Ju et al., “MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B,” The Journal of Immunology, vol. 191, no. 1, pp. 293–301, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Rüster, S. Göttig, R. Ludwig et al., “Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells,” Blood, vol. 108, no. 12, pp. 3938–3944, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Lourenco, V. Teixeira, T. Kalber, R. J. Jose, R. A. Floto, and S. M. Janes, “Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors,” The Journal of Immunology, vol. 194, no. 7, pp. 3463–3474, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Yan, X. Song, W. Yu et al., “Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects,” Tumour Biology, vol. 37, no. 6, pp. 8425–8435, 2016. View at Google Scholar
  17. A. Poggi, A. Musso, I. Dapino, and M. Zocchi, “Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells,” Immunology Letters, vol. 159, no. 1–2, pp. 55–72, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Chiesa, S. Morbelli, S. Morando et al., “Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 42, pp. 17384–17389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. K. English, F. P. Barry, and B. P. Mahon, “Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation,” Immunology Letters, vol. 115, no. 1, pp. 50–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. X. X. Jiang, Y. Zhang, B. Liu et al., “Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells,” Blood, vol. 105, no. 10, pp. 4120–4126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Zhang, W. Ge, C. Li et al., “Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells,” Stem Cells and Development, vol. 13, no. 3, pp. 263–271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. J. Nauta, A. B. Kruisselbrink, E. Lurvink, R. Willemze, and W. E. Fibbe, “Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells,” The Journal of Immunology, vol. 177, no. 4, pp. 2080–2087, 2006. View at Publisher · View at Google Scholar
  23. V. Volarevic, N. Arsenijevic, M. L. Lukic, and M. Stojkovic, “Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus,” Stem Cells, vol. 29, no. 1, pp. 5–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Favre, J. Mold, P. W. Hunt et al., “Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease,” Science Translational Medicine, vol. 2, no. 32, article 32ra36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Ito, M. Hoshi, H. Ohtaki et al., “Ability of IDO to attenuate liver injury in alpha-galactosylceramide-induced hepatitis model,” Journal of Immunology, vol. 185, no. 8, pp. 4554–4560, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Matteoli, E. Mazzini, I. D. Iliev et al., “Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction,” Gut, vol. 59, no. 5, pp. 595–604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Rasmusson, M. Uhlin, K. Le Blanc, and V. Levitsky, “Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes,” Journal of Leukocyte Biology, vol. 82, no. 4, pp. 887–893. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Prigione, F. Benvenuto, P. Bocca, L. Battistini, A. Uccelli, and V. Pistoia, “Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells,” Stem Cells, vol. 27, no. 3, pp. 693–702, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. G. M. Spaggiari, A. Capobianco, H. Abdelrazik, F. Becchetti, M. C. Mingari, and L. Moretta, “Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2,” Blood, vol. 111, no. 3, pp. 1327–1333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. P. A. Sotiropoulou, S. A. Perez, A. D. Gritzapis, C. N. Baxevanis, and M. Papamichail, “Interactions between human mesenchymal stem cells and natural killer cells,” Stem Cells, vol. 24, no. 1, pp. 74–85, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. W. Li, G. Ren, Y. Huang et al., “Mesenchymal stem cells: a double-edged sword in regulating immune responses,” Cell Death & Differentiation, vol. 19, no. 9, pp. 1505–1513, 2012. View at Publisher · View at Google Scholar · View at Scopus